Advancing Knowledge at the Intersection of Neuropsychopharmacology and Addiction

Giovanni Martinotti; Stefania Chiappini

doi:10.53941/cna.2025.100001

Clinical Neuropsychopharmacology and Addiction ›› 2025, Vol. 1 ›› Issue (1) :1 DOI: 10.53941/cna.2025.100001

Editorial

research-article

Advancing Knowledge at the Intersection of Neuropsychopharmacology and Addiction

Giovanni Martinotti ¹^,²
, Stefania Chiappini ³^,^*

Author information +

History +

PDF (1634KB)

Cite this article

Download citation ▾

Giovanni Martinotti, Stefania Chiappini. Advancing Knowledge at the Intersection of Neuropsychopharmacology and Addiction. Clinical Neuropsychopharmacology and Addiction, 2025, 1(1): 1 DOI:10.53941/cna.2025.100001

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Martinotti, G.; Vita, A.; Fagiolini, A.; et al. Real-world experience of esketamine use to manage treatment-resistant depression: A multicentric study on safety and effectiveness (REAL-ESK study). J. Affect. Disord. 2022, 319, 646-654. https://doi.org/10.1016/j.jad.2022.09.043.

[2]	Johansen, L.; Liknaitzky, P.; Nedeljkovic, M.; et al. How psychedelic-assisted therapy works for depression: Expert views and practical implications from an exploratory Delphi study. Front. Psychiatry 2023, 14, 1265910. https://doi.org/10.3389/fpsyt.2023.1265910.

[3]	Perkins, D.; Sarris, J.; Rossell, S.; et al. Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm. Aust. N. Z. J. Psychiatry 2021, 55, 1127-1133. https://doi.org/10.1177/0004867421998785.

[4]	Lima-Ojeda, J.M.; Rupprecht, R.; Baghai, T.C. Neurobiology of depression: A neurodevelopmental approach. World J. Biol. Psychiatry 2018, 19, 349-359. https://doi.org/10.1080/15622975.2017.1289240.

[5]	Maj, M.; Stein, D.J.; Parker, G.; et al. The clinical characterization of the adult patient with depression aimed at personalization of management. World Psychiatry 2020, 19, 269-293. https://doi.org/10.1002/wps.20771.

[6]	McIntyre, R.S.; Alsuwaidan, M.; Baune, B.T.; et al. Treatment-resistant depression: Definition, prevalence, detection, management, and investigational interventions. World Psychiatry 2023, 22, 394-412. https://doi.org/10.1002/wps.21120.

[7]	Volkow, N.D.; Blanco, C. Substance use disorders: A comprehensive update of classification, epidemiology, neurobiology, clinical aspects, treatment and prevention. World Psychiatry 2023, 22, 203-229. https://doi.org/10.1002/wps.21073.

[8]	Schifano, F.; Napoletano, F.; Chiappini, S.; et al. New/emerging psychoactive substances and associated psychopathological consequences. Psychol. Med. 2021, 51, 30-42. https://doi.org/10.1017/S0033291719001727. Erratum in: Psychol. Med. 2021 , 51 , 43. https://doi.org/10.1017/S003329171900254X.

[9]	Sampogna, G.; Toni, C.; Catapano, P.; et al. New trends in personalized treatment of depression. Curr. Opin. Psychiatry 2024, 37, 3-8. https://doi.org/10.1097/YCO.0000000000000903.